Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates

Canagliflozin 100 mg and 300 mg are associated with HbA1c reductions of -0.67% and -0.79%, respectively.

• Dapagliflozin 10 mg resulted in an HbA1c reduction of -0.41%, while empagliflozin 10 mg and 25 mg showed reductions of -0.57% and -0.64%, respectively.
• Probabilities of canagliflozin 100 mg outperforming dapagliflozin and empagliflozin were 79%, 60%, and 53%, respectively.
• Canagliflozin 300 mg had probabilities of 88%, 72%, and 65% for outperforming dapagliflozin and empagliflozin.
• The calculated cost per 1%-point reduction in HbA1c was lower for canagliflozin at $448 and $422 compared to dapagliflozin at $785 and empagliflozin at $527 and $563.

AI simplified